Gland Pharma Limited has announced the approval of 690,019 employee stock options under its ESOP 2025 scheme. The grant covers 124 employees and is structured with two different pricing tiers, including options at a 50% discount to the market price and others at the INR 1 face value. The vesting schedule spans three years, beginning in May 2027, with a two-year exercise period following each vesting date.
Stock Option Grant Details
On May 15, 2026, the company’s ESOP Compensation Committee authorized the issuance of 690,019 stock options to 124 eligible employees. This initiative is part of the ESOP 2025 scheme, designed to align employee interests with the long-term growth and performance of the organization.
Pricing and Structure
The grant includes two distinct categories of options:
- 455,413 options priced at INR 934.15, which represents 50% of the closing share price on the grant date.
- 234,606 options priced at INR 1, matching the face value of the company’s equity shares.
Vesting and Exercise Schedule
The granted options follow a structured multi-year vesting timeline:
- 34% of the options will vest on May 15, 2027.
- 33% will vest on May 15, 2028.
- 33% will vest on May 15, 2029.
Following the date of vesting, employees are provided with a maximum period of two years to exercise their respective options, ensuring a flexible transition for participants in the scheme.
Source: BSE
